CL-197

• Description :

  CL-197 is an orally active and long-acting purine anti-HIV nucleoside reverse transcriptase inhibitor (NRTI) . CL-197 has potential effect on the research of viral, oncological and cerebrovascular diseases[1]. CL-197 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• UNSPSC :

  12352005

• Target :

  HIV Protease

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/cl-197.html

• Purity :

  99.32

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O[C@H]1[C@H](F)[C@H](N2C=NC3=C(N)N=C(F)N=C32)O[C@@]1(CO)C#C

• Molecular Formula :

  C12H11F2N5O3

• Molecular Weight :

  311.24

• References & Citations :

  [1]Hou J, et al. 4'-Ethynyl-2'-deoxy-2'-β-fluoro-2-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection. J Med Chem. 2023 Aug 24;66 (16) :11282-11293.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [1030595-07-3]